Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regional Coverage

Asia Pacific

Set Alert for Asia Pacific

Latest From Asia Pacific

Glenmark Spins Out Business To Drive Value

Glenmark has drawn private equity interest for its carved out domestic orthopedic and pain management business as it seeks to fuel growth in these segments and pare debt via the proceeds. A similar strategy may be deployed for the firm's active pharmaceutical ingredients unit.

Commercial Deals

Rough Patch For Lupin, Much Riding On Solosec, Enbrel Biosimilar

An under pressure US business dented Lupin in Q1, with a recovery seen only in the second half of FY19 as new generic products roll out. A ramp-up in on-market products like Solosec in the US and a smooth run to launch for biosimilar Enbrel in Japan and the EU, among other products, could be vital to restore momentum for the Indian firm.

Strategy India

Robust Appetite For Biosolution IPO As OA Cell Therapy Nears Commercialization

Biosolution's IPO, which was priced at the high end of the range despite dampened biotech sentiment following the arrest of Nature Cell's CEO, is poised to help accelerate commercialization of the South Korean cell therapy company's osteoarthritis treatment CartiLife and the progress of other pipeline assets.

South Korea Financing

Home Gains Buoy Cipla In Q1 But US Momentum Pivotal

A strong run on home turf lifted Cipla in Q1, but US momentum with differentiated launches is what investors are keeping a sharp eye on. A China play in the respiratory space is also on the cards for the Indian firm.
India Commercial

Takeda Alliance Boosts Liver Disease Venture Ambys’s $140m Launch

Takeda is investing in newly launched serious liver disease company Ambys Medicines to support the advancement of the US venture’s platform and pipeline, in line with its core strategic therapeutic priorities.

Liver & Hepatic Japan

A Safe Harbor For Biotechs? Ascletis, BeiGene Mark Early Wins For HK Exchange

The market debuts of BeiGene and Ascletis on the new Hong Kong Stock Exchange’s Biotech section could further encourage other Chinese biotech companies as they seek to draw in a wider pool of investors and focus on the promising domestic sector.

Hong Kong Commercial
See All

Europe

Set Alert for Europe

Latest From Europe

Esmya Review Held Back Gedeon Richter in First Half

Sales of the uterine fibroid therapy, Esmya, sharply declined during the first half of 2018 at Hungary's specialty pharmaceuticals company, but an EU review of a potential association between the drug and liver injury has now been completed.

 

Gynecology & Urology Drug Safety

UCB Looks To Its Next Wave Of Innovative Products

Early clinical-stage products for neurological and autoimmune diseases are progressing through the European biopharma's pipeline.

Immune Disorders Neurology

Pre-Brexit: UK Biotechs Still Dominate European Fundraising

Using data provided by Informa Pharma Intelligence, the UK BioIndustry Association reports that UK biotechs continue to take the lion's share of European fundraising.

 

Europe Analysis

Lysosomal Storage Disorders: Azafaros Takes Aim At Small Molecules

BioGeneration Ventures has given birth to a new European biotech, Azafaros, supplying seed funding for the development of a new generation of compounds to tackle rare metabolic disorders.

 

Financing Rare Diseases

Aurobindo Aims For Europe Growth With Apotex Acquisitions

The Indian drug maker is handing over €74m to Canada's Apotex, buying the latter's operations in Poland, the Czech Republic, the Netherlands, Spain and Belgium and adding over 200 generics and more than 80 OTC products to its portfolio.

M & A Generic Drugs

France's Dynacure Gets VC Backing To Progress Antisense Candidate For Myopathy

Clinical trials are expected to start next year with an antisense clinical candidate for the rare disease, centronuclear myopathy, developed by French start-up Dynacure as part of its collaboration with US antisense specialist Ionis Pharmaceuticals.

 

Financing Rare Diseases
See All

United States

Set Alert for United States

Latest From United States

Insmed’s Amikacin Moves Closer To US Market In Refractory Lung Disease

FDA panel's recommendation that liposome inhalation suspension be labeled only for refractory nontuberculous mycobacterial lung disease and not first-line use aligns with analyst expectations; panel cites lack of clinical studies in treatment-naive patients and adverse event profile as reasons for limiting drug to patients with limited or no treatment options.


Infectious Diseases Respiratory

Takeda Alliance Boosts Liver Disease Venture Ambys’s $140m Launch

Takeda is investing in newly launched serious liver disease company Ambys Medicines to support the advancement of the US venture’s platform and pipeline, in line with its core strategic therapeutic priorities.

Liver & Hepatic Japan

Express Scripts Rewards Low List-Priced Brands In 2019 Formulary, Retains Focus On Rebates

Mylan’s Symfi and Merck’s Zepatier gain preferred status on PBM's national preferred formulary for 2019. But more drugs are excluded from coverage – 242, up from 196 in 2018.

Pharmacy Benefit Management Pricing Strategies

Yuhan Licenses Out Degenerative Disc Therapy To Spine Despite Earlier Trial Failure

South Korean pharma firm licenses out to US venture Spine Biopharma novel peptide drug for degenerative disc disease YH14618, despite a Phase II failure and trial halt in 2016.

South Korea United States

Who's Promised What: A Guide To Pharma Drug Pricing Pledges

Pharma companies have responded to mounting political pressure to lower drug prices by pledging to limit increases and even roll back the costs of certain drugs, but it's hard to keep track of who has promised what exactly. Here, Scrip provides a listing of pharma pricing pledges.

Companies Pricing Debate

ViroMed's Plasmid DNA Facility Buy Addresses Key Potential US Regulatory Hurdle

ViroMed, which is progressing Phase III clinical trials for its gene therapy VM202 in the US, has acquired a plasmid DNA manufacturing facility in San Diego, a move that will enable the South Korean biotech to provide stable supplies of the product if approved, and addressing a major uncertainty for gene therapies seeking regulatory approval from the FDA.

Biologics United States
See All
Advertisement
UsernamePublicRestriction

Register